Enlivex, a cell immunotherapy company, is developing an autologous and allogeneic  drug pipeline for the treatment of autoimmune and inflammatory conditions which involved over-expression or hyper-expression of cytokines (Cytokine Release Syndrome) such as CAR-T (Chimeric Antigen Receptor) cancer treatment procedures, Graft-versus-Host disease (GvHD) resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis,  and other disorders. Our revolutionary approach to inducing immune tolerance by injecting apoptotic cells which interact with dendritic cells, or cells that, among other things, clear apoptotic cells from the body.  Dendritic cells that clear and process apoptotic cells undergo a process of toleration as it relates to the immune system’s response, causing a decrease to normal levels of over-expression or hyper-expression of cytokines.

Our clinical development programs focus on GvHD, CAR-T and autoimmune diseases. Our most advanced product candidate, Allocetra™, has been developed for the prevention of acute GvHD, particularly severe, or high-grade (i.e., Grades II-IV), acute GvHD.  Additionally, we are currently examining the potential for collaborating with leading CAR-T companies in clinical studies to evaluate the efficacy and side effect profile of CAR-T treatments for a variety of cancer-related clinical indications, such as blood cancers and solid tumors.